Onconova strikes first deal for lead project rigosertib
This article was originally published in Scrip
Executive Summary
The private US firm Onconova Therapeutics has signed the first commercial deal for its lead development project rigosertib, linking up with the Japanese bioventure SymBio Pharmaceuticals for the development and commercialisation of the multi-kinase inhibitor in Japan and South Korea.